Psychedelic Therapy in the UK: Every Legal Route in 2026

If you are considering psychedelic-assisted treatment in the UK — for yourself or for someone close to you — the picture in July 2026 is uneven by design. Esketamine is licensed here, yet the public route to it barely exists in England; private ketamine clinics fill the gap at self-pay prices; and psilocybin and MDMA are available only inside research, where the UK happens to run one of the busiest programs in Europe. Which door is open to you depends on where you live and on your documented treatment history. This guide covers who qualifies for each route, how to start, what it costs, and what to realistically expect; you can begin orienting yourself with our eligibility check.

At a glance

Esketamine (Spravato): one licence, three answers

Esketamine nasal spray is licensed in the UK, but whether the NHS will pay for it depends on where you live. In technology appraisal TA854, NICE concluded that esketamine's cost-effectiveness case for treatment-resistant depression was not made and did not recommend it for routine NHS use — a decision that applies in England and Wales, and which Northern Ireland endorsed rather than issuing its own separate recommendation. In practice this means a GP or psychiatrist in those nations cannot simply prescribe Spravato on the NHS.

Scotland is the exception. The Scottish Medicines Consortium accepted esketamine for restricted use in treatment-resistant depression under a patient access scheme, so NHS Scotland patients can be assessed for it through their psychiatrist, subject to local health board arrangements. If you live in Scotland, ask your psychiatrist directly about the esketamine pathway in your board area — do not assume the England picture applies to you. The practical currency everywhere is a written treatment history: every antidepressant tried in the current episode, with dose, duration and outcome. Bring it to the first appointment — it does more work than anything you say in the room.

Private ketamine clinics: the main route in England

Off-label ketamine treatment from a licensed doctor is legal — ketamine, unlike the classical psychedelics, is a Schedule 2 medicine with recognised medical uses — and a private market of infusion and ketamine-assisted psychotherapy (KAP) clinics has grown around the NHS gap. Independent clinics must be registered with the Care Quality Commission in England (or the Scottish and Welsh equivalents). Check the clinic's CQC profile and its latest rating, and the prescriber on the GMC register, before paying anything.

Expect roughly £300–800 per infusion; typical London pricing sits around £595 per infusion plus an initial consultation, and full KAP programs run from about £6,000 for six weeks. A small number of specialist services exist inside the NHS itself but on a self-funded basis — the ketamine service for treatment-resistant depression at Oxford Health suggests budgeting around £3,000 per year.

One development to watch: the NHS has begun piloting racemic ketamine within existing depression care pathways, through programs at Oxford Health NHS Foundation Trust and Central and North West London NHS Foundation Trust (Magnetar/Blossom reimbursement report, 2025). These are limited-capacity services accessed through NHS referral, not something you can book directly, but they are the first crack in the "private-only" picture.

Red flags matter doubly in a self-pay market: no psychiatric screening before payment, no psychiatrist involvement, no published prices, guaranteed results, or pressure to prepay long packages. Our clinic-choice guide has the full checklist, and you can browse listed providers in the UK to compare. For how the UK's self-pay picture compares with the rest of the continent, see our Europe-wide reimbursement map.

Psilocybin: research-only, with a genuinely active pipeline

Psilocybin remains a Class A, Schedule 1 substance in the UK — the schedule for drugs with no recognised medicinal use — so there is no prescription, compassionate-access or private-clinic route, and anyone selling psilocybin therapy in the UK today is operating illegally. The government accepted advisory recommendations in 2025 to reduce research friction around Schedule 1 substances, but as of spring 2026 that implementation work was still in progress and does not change patient access (Blossom UK country report).

What the research route honestly looks like in July 2026:

• Compass Pathways' COMP360 Phase 3 program for treatment-resistant depression — the largest psilocybin program in the world, with UK sites — has finished recruiting; both pivotal trials (NCT05624268 and NCT05711940) are active but no longer enrolling, so this is a program to watch for results, not to join.
• Cybin's EMBRACE Phase 3 trial of CYB003, a deuterated psilocin analog, for major depressive disorder is recruiting at UK sites (NCT06793397).
• A Phase 2 trial comparing 5 mg and 25 mg psilocybin with psychological support in generalised anxiety disorder began recruiting in the UK in April 2026 (Blossom trial tracker).
• Imperial College London's PsiloIMAGINE study, an early-phase psilocybin trial for young people with self-harm, is recruiting (NCT06798636), and University College London is recruiting for a psilocybin preparation study (DIPP).

Academic groups at Imperial and King's College London anchor the scene, and dedicated commercial research sites such as Clerkenwell Health in London run psychedelic studies for multiple sponsors and recruit patients on an ongoing basis. Participation is free, screening is strict, and enrolment is never guaranteed — but in the UK this is a real option rather than a theoretical one.

MDMA: research-only, and no UK trial is recruiting

MDMA is also Class A and Schedule 1, with no medical-access route. The honest status: as of July 2026, no UK MDMA trial is listed as recruiting on ClinicalTrials.gov. The most recent UK-linked study of an MDMA-type compound — a Phase 2 trial of EMP-01, an MDMA derivative, in social anxiety disorder — completed in 2025 (Blossom UK country report). If MDMA-assisted therapy matters to you, the realistic options are watching the registries for new UK studies or considering trial sites elsewhere in Europe — our trials guide explains how to search and what participation involves. Anyone offering MDMA therapy commercially in the UK today is operating illegally.

Clinical trials in the UK

The research route is unusually strong here. Blossom currently tracks 67 psychedelic clinical trials connected to the UK, 12 of them active, spanning psilocybin, ketamine, DMT, 5-MeO-DMT and esketamine, with treatment-resistant depression the most-studied condition (Blossom UK country report). London is the centre of gravity — Imperial, King's, UCL and commercial sites such as Clerkenwell Health — with Oxford and Cambridge as supporting nodes. Recruiting studies in mid-2026 include the CYB003 Phase 3 depression trial, the psilocybin generalised-anxiety trial, a ketamine trial for depression with anorexia nervosa, and Imperial's PsiloIMAGINE. Participation is free and legal, but screening is strict and enrolment is never guaranteed. See the trials guide for how phases, placebo and consent work, and search ClinicalTrials.gov for current UK listings.

What to expect in treatment

Whichever route you take, the shape of care is similar and worth picturing in advance. It begins with a screening appointment: the clinician reviews your psychiatric and medication history, checks your cardiovascular health and current medicines, and confirms the diagnosis before anything is scheduled. This is also where contraindications are caught — and in a self-pay market, a clinic that skips this step is telling you something.

A ketamine infusion is typically given intravenously over about 40–60 minutes while staff monitor blood pressure, heart rate and how you feel, followed by a recovery and observation period before you leave. Dissociation and a temporary rise in blood pressure are expected during the session and settle as the drug clears. You must not drive until the next day, so arrange a ride home. KAP programs wrap the dosing in preparation and integration sessions with a therapist.

Where esketamine is available — via NHS Scotland — you self-administer the nasal spray under supervision and stay for an observation period of roughly two hours, always in combination with an oral antidepressant. In every setting the medicine is one part of the plan: screening, monitoring and follow-up are what make it safe, and psychotherapy or integration is what helps the effect last.

Risks and who should not start

These treatments are generally well tolerated under supervision, but they are not for everyone — which is exactly what screening is for. Common, transient effects during or shortly after a session include dissociation (a detached, dreamlike feeling), nausea, mild perceptual changes, and a short-lived rise in blood pressure and heart rate; these resolve as the drug is metabolised. Treatment may be inappropriate, or require particular caution and specialist evaluation, when any of the following apply:

• Uncontrolled hypertension or significant cardiovascular instability, including a history of aneurysmal vascular disease, because of the temporary rise in blood pressure.
• A personal or family history of psychosis or bipolar disorder — a particular caution for classic psychedelics such as psilocybin in the trial setting, where study screening is careful.
• Pregnancy or breastfeeding.
• Substance-use concerns, particularly patterns of compulsive use — a point to raise honestly, since ketamine itself carries misuse potential.

A responsible provider screens for all of these before taking your money. If a clinic is willing to treat you without that assessment, treat it as a warning sign. To see who is listed near you, browse providers in the UK.

Frequently asked questions

Can my GP refer me for Spravato on the NHS in England, Wales or Northern Ireland?

Realistically no — NICE's TA854 decision means it is not routinely commissioned in England and Wales, and Northern Ireland endorsed the same appraisal. Your GP can refer you to secondary care to discuss alternatives, including specialist ketamine services and trials.

I live in Scotland — how do I start?

Ask your psychiatrist about the esketamine pathway in your health board area. The SMC accepted Spravato for restricted use under a patient access scheme, and the assessment turns on documented treatment resistance, so bring your written medication history.

Is private ketamine treatment legal?

Yes. Off-label prescribing by a licensed doctor is lawful, and the clinic must be CQC-registered (in England) as an independent healthcare provider. Legal does not mean uniformly good — check the CQC rating, the prescriber's GMC number, the screening process and the full course cost before paying.

Can I get psilocybin therapy in the UK right now?

Only inside a clinical trial. Psilocybin is Class A and Schedule 1, with no prescription or compassionate route. Several UK trials are recruiting in 2026 — including a Phase 3 depression study and a generalised-anxiety study — and participation is free.

What about MDMA therapy?

Not outside research, and as of July 2026 no UK MDMA trial is recruiting. Watch the registries or consider trial sites elsewhere in Europe; anyone selling MDMA therapy in the UK today is acting illegally.

Do trials pay me to participate?

Patient trials do not pay for participation, but travel reimbursement is common, and all study procedures are free. Anyone charging you for "trial access" is a scam.

Sources

1. NICE TA854: Esketamine for treatment-resistant depression
2. SMC: Esketamine (Spravato) advice — SMC2258
3. Blossom: United Kingdom country report
4. Psychedelic Alpha: Worldwide psychedelic laws tracker
5. Care Quality Commission
6. Oxford Health NHS FT: ketamine service pricing
7. The Burlington Clinic: ketamine therapy cost in London
8. Eulas Clinics: ketamine therapy pricing
9. Magnetar/Blossom: Psychedelics and reimbursement report (2025)
10. ClinicalTrials.gov: NCT06793397 — CYB003 Phase 3 in major depressive disorder (recruiting, UK sites)
11. ClinicalTrials.gov: NCT05711940 — COMP360 Phase 3 in treatment-resistant depression (active, not recruiting)
12. ClinicalTrials.gov: NCT06798636 — PsiloIMAGINE, Imperial College London (recruiting)
13. Clerkenwell Health

This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Regulations and prices change; always verify a provider's current registration with the CQC or the relevant regulator and discuss your options with a licensed clinician who knows your history. If you are in crisis, contact your local emergency number or a crisis line immediately.

This guide awaits review by a licensed medical professional.